Monoclonal Antibody Therapy
|Aug 17 - Jun 29, 2022|
On January 24, 2022, the U.S. Food and Drug Administration reissued the emergency use authorizations for Eli Lilly’s bamlanivimab-etesevimab and Regeneron’s REGEN-COV monoclonal antibody therapy treatments, which states that these treatments are not authorized for use in any U.S. state, territory, or jurisdiction at this time.
Unfortunately, as a result of this abrupt decision made by the federal government, all state-supported monoclonal antibody therapy treatment sites will be closed until further notice. The full Florida Department of Health press release can be found here.